Clinical trial registry record

A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated April 13, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT05637255
Last registry update
April 13, 2026
Status
Completed
Phase
Phase 2
Sponsor
Sylentis, S.A.
Enrollment
99
Countries
Czechia, Poland, Slovakia
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
Evidence population
Human clinical study registration
Participants
99
Population
ALL · 50 Years to 85 Years
Duration
2022-11-22 to 2024-12-19
Intervention
SYL1801
Comparator
Not reported
Outcomes measured
Change from Baseline on visual acuity on Day 42 after last instillation of the assigned dose level — 42 days after firs…; Proportion of subjects within each cohort who maintained visual acuity on Day 42 after last instillation of the assigne…; Proportion of subjects within each cohort who gained visual acuity on Day 42 after last instillation of the assigned do…; Proportion of subjects within each cohort who needed rescue medication at any point of the study — Through study comple…; Change from Baseline on flow area on Day 42 after last instillation of the assigned — 42 days after first administration; Change from Screening on leakage area on Day 42 after last instillation of the assigned — 43 days after first administr…; Change from Baseline on intraocular pressure (IOP) — 42 days after first administration; Adverse Event Evaluation — Through study completion, up to 42 days
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON